Health
Novel nasal spray reduces viral replication by up to 96%: according to COVID-19 challenge study – BioPharma-Reporter.com
Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
The novel nasal spray, INNA-051, is being developed by Australian biotech Ena Respiratory. The company has published its animal study, led by Public Health Englands Deputy Director Professor Miles Carroll, on biomedical pre-publication research site medRxiv.
The researchers note that INNA-051 significantly reduced COVID-19 virus levels in the nose and throat. A nasal administration delivered once or twice a week could be used to prevent infection in at-risk populations and healthcare workers, s…
-
General21 hours agoNovo Nordisk names new CEO amid share price slump and concerns over Wegovy, Ozempic sales
-
General17 hours agoOne-in-10 students need extra school support: NAPLAN
-
Noosa News24 hours agoBrisbane poaches arts visionary to shape festival’s future
-
Noosa News15 hours agoQueensland in the dark on beef import biosecurity threat: Perrett